Evidence map›Paper›PMID 39532398›Full record

Trial reportDiabetes, obesity & metabolism2025

De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).

Paloma Rodriguez, Nikki Breslaw, Huijun Xiao, Jim Bena, Kimberly Jenkins, Diana Isaacs, Keren Zhou, Marcio L Griebeler, Bartolome Burguera, Kevin M Pantalone and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04538352. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04538352 phase4completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial

Ran2021Enrolled60Registered outcomes6Posted comparisons2ConditionsType 2 DiabetesArmsInsulin Aspart, insulin degludec, semaglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Endocrinology: What You May Have Missed in 2024.Annals of internal medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paloma RodriguezDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Nikki BreslawLerner Research Institute, Clinical Research Unit, Cleveland Clinic, Cleveland, Ohio, USA.
Huijun XiaoDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Jim BenaDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
Kimberly JenkinsDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Diana IsaacsDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Keren ZhouDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Marcio L GriebelerDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Bartolome BurgueraDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Kevin M PantaloneDepartment of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-3897-4551
TRANSITION‐T2D Investigators

Funding

Investigator Sponsored Studies ProgramNovo Nordisk Inc
6 · The paper itself

Abstract

aimsThe study aims to examine the outcome of replacement of prandial insulin with once-weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections (MDI). MATERIALS AND

methodsThis single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day. Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI. The primary outcome was percentage of subjects maintaining HbA1c ≤7.5% (58 mmol/mol) at Week 26.

resultsAt Week 26, 90% of semaglutide and 75% of MDI subjects maintained HbA

conclusionsIn people with type 2 diabetes well controlled (HbA

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsInsulin, Long-ActingAdultAgedBlood GlucoseDrug Administration ScheduleDrug Therapy, CombinationFemaleGlycemic ControlHumansHypoglycemiaInjections, SubcutaneousInsulinBlood GlucoseGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulininsulin degludecInsulin, Long-ActingSemaglutidebasal bolusbody weightGLP‐1 agonistglycaemic controltype 2 diabetesweight change

Identifiers

PMID39532398
PMCPMC11701190

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.